Skip to content
DataLookout
Menu

NCT06758401

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

StatusRecruiting
PhasePhase 3
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 20 versions: 18 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 389 → 392 locations
  2. Notable Eligibility criteria expanded, about 74 words
    • Trial sites expanded: 372 → 389 locations
    • Secondary endpoints: 11 to 13
    • Publications: details revised at 1 of 1 entry
  3. Minor Trial sites expanded: 329 → 372 locationsv18
  4. Minor Study sites: 330 to 329v17
  5. Minor Trial sites expanded: 315 → 330 locationsv16
Show 12 earlier versionsHide 12 earlier versions
  1. Minor Study sites: 296 to 315v15
  2. Minor Study sites: 241 to 296v14
  3. Minor Study sites: 152 to 241v13
  4. Minor Study sites: 106 to 152v12
  5. Minor Study sites: 62 to 106v11
  6. Notable Start date: May 4, 2025 to Jul 23, 2025
    • Study sites: 46 to 62
    v10
  7. Minor Study sites: 22 to 46v9
  8. Minor Study sites: 7 to 22v7
  9. Minor Study sites: 3 to 7v6
  10. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 4 words
    • Study sites: 0 to 3
    • Start date changed from estimate of May 31, 2025 to May 4, 2025
    v5
  11. Notable Eligibility criteria expanded, about 8 words
    • Study sites: 5 to 0
    v3
  12. Notable Start date: Jan 20, 2025 to May 31, 2025
    • Study sites: 0 to 5
    • Primary completion date: Aug 24, 2028 to Sep 5, 2028
    • Study completion date: Feb 17, 2029 to Mar 1, 2029
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Survival
Timeframe: Baseline to date of death from any cause (Approximately 2 years).
Progression Free Survival (PFS) assessed by blinded independent central review (BICR)
Timeframe: From Baseline to to date of first documentation of progression OR death (Approximately 2 years).

Secondary (13)

Progression Free Survival as assessed by Investigator
Objective Response Rate as assessed by BICR
Objective Response Rate as assessed by Investigator
Duration of Response as assessed by BICR
Duration of Response as assessed by Investigator
Show 8 moreShow less
Number of participants with adverse events (AEs)
Pharmacokinetics (PK) of antibody-conjugated monomethyl auristatin E (ac-MMAE) in plasma: Plasma concentration at end of infusion (CEOI)
PK of ac-MMAE in plasma: Plasma predose concentration (Cpredose)
PK of unconjugated monomethyl auristatin E (MMAE) in plasma: Plasma concentration at end of infusion (CEOI)
PK of MMAE in plasma: Plasma predose concentration (Cpredose)
Number of participants with antidrug antibodies (ADAs)
Time to response (TTR) using RECIST v1.1 as assessed by BICR
TTR using RECIST v1.1 as assessed by investigator

Arms and interventions

Sigvotatug Vedotin with PembrolizumabExperimental

Participants will receive Sigvotatug Vedotin, administered as an IV infusion and pembrolizumab, administered as an IV infusion.

Pembrolizumab MonotherapyActive comparator

Participants will receive pembrolizumab, administered as an IV infusion.

Drugs: Sigvotatug Vedotin, Pembrolizumab

Sites

392 sites in 31 countries

United States 85, China 31, Brazil 26, Germany 21, Japan 20, Argentina 19, Spain 18, Turkey (Türkiye) 16, France 14, Chile 12, Italy 12, Romania 10, South Korea 10, Australia 9, United Kingdom 9, Greece 8, India 8, Taiwan 8, Poland 7, Bulgaria 6, Slovakia 6, Belgium 5, Czechia 5, Netherlands 5, Austria 4, Canada 4, Hungary 4, Mexico 4, Israel 2, Saudi Arabia 2, Switzerland 2